Department of Orthopedic and Spine surgery, Dr. Babasaheb Ambedkar Central Railway Hospital, Mumbai, India.
Spine (Phila Pa 1976). 2022 Jan 15;47(2):E58-E63. doi: 10.1097/BRS.0000000000004131.
Prospective randomized control trial.
The aim of this study was to analyze role of cerebrolysin in patients of degenerative cervical myelopathy (DCM) managed by surgical modalities.
Cerebrolysin has been extensively researched with variable success in neurodegenerative pathologies. There has been only one study in published literature till date that has studied role of cerebrolysin in DCM in conservatively managed patients but none in the patients treated surgically. We present our pilot study which analyzes the role of cerebrolysin in patients of DCM managed by surgical modalities.
This prospective randomized control trial was conducted at a tertiary care institute in Mumbai. Sixty operated cases of DCM were randomly divided into 2 groups. The first group was given Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively. The second group was given placebo. Modified Japanese Orthopedic Association scores (mJOA) and visual analog scale (VAS) were used to document functional outcomes at 3 weeks, 3 months, 6 months, and 1 year. Recovery of hand function was separately accessed by improvement in hand power and sensations.
Preoperative mJOA and VAS scores were comparable between 2 groups. Both groups showed significant improvement in both mJOA and VAS scores at 3weeks, 3 months, 6 months and 1-year follow-up (P < 0.01). In comparing the two groups, there was no difference in improvement of mJOA and VAS scores. However, cerebrolysin group showed significant improvement in hand function at 1 year compared to the placebo. Postoperative neurological recovery was better in the cerebrolysin group with 66.7% patients showing complete neurological recovery compared to 56.7% for placebo, but this was statistically insignificant. Two patients developed headache and one patient complained of dizziness in the cerebrolysin group, but these resolved without any intervention.
Use of cerebrolysin in postoperative cases of DCM is safe and results in improved hand function.Level of Evidence: 1.
前瞻性随机对照试验。
本研究旨在分析脑活素在手术治疗退行性颈椎病(DCM)患者中的作用。
脑活素在神经退行性病变方面的研究取得了不同程度的成功。迄今为止,发表的文献中只有一项研究研究了脑活素在保守治疗的 DCM 患者中的作用,但没有研究手术治疗的患者。我们提出了我们的初步研究,分析了脑活素在手术治疗的 DCM 患者中的作用。
这项前瞻性随机对照试验在孟买的一家三级保健机构进行。将 60 例 DCM 手术患者随机分为 2 组。第一组术后每天给予 5ml 脑活素注射液,用 100ml 生理盐水稀释,持续 21 天,每天 1 次。第二组给予安慰剂。使用改良日本骨科协会评分(mJOA)和视觉模拟评分(VAS)在术后 3 周、3 个月、6 个月和 1 年记录功能结果。手功能的恢复分别通过手部力量和感觉的改善来评估。
两组患者术前 mJOA 和 VAS 评分无差异。两组在术后 3 周、3 个月、6 个月和 1 年随访时 mJOA 和 VAS 评分均有显著改善(P < 0.01)。两组间 mJOA 和 VAS 评分的改善无差异。然而,脑活素组在 1 年后手部功能明显改善,与安慰剂组相比,66.7%的患者出现完全神经恢复,而安慰剂组为 56.7%,但无统计学意义。脑活素组有 2 例出现头痛,1 例出现头晕,但无需干预即可缓解。
脑活素在 DCM 术后患者中使用是安全的,可改善手部功能。
1。